Gangloff Scott A. 4
4 · Akero Therapeutics, Inc. · Filed Aug 19, 2025
Insider Transaction Report
Form 4
Gangloff Scott A.
Chief Technology Officer
Transactions
- Exercise/Conversion
Common Stock
2025-08-15$19.62/sh+2,600$51,012→ 26,351 total - Exercise/Conversion
Stock option (Right to Buy)
2025-08-15−2,600→ 17,784 totalExercise: $19.62Exp: 2034-04-28→ Common Stock (20,384 underlying)
Footnotes (1)
- [F1]Twenty-five (25) percent of the shares subject to this option shall vest and become exercisable on April 29, 2025, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.